Osiris ( Osiris)

Primary tabs

Osiris's picture

Management

Contact Address

About Osiris

Osiris Therapeutics, Inc. is a leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, orthopedic and cardiovascular areas. Osiris’ stem cell products have significant therapeutic potential because of their ability to regulate inflammation, promote tissue regeneration and prevent pathological scar formation.

Osiris press release, blog etc

Tue, 03/12/2019 - 04:55 Smith & Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc.
Tue, 03/12/2019 - 04:54 Osiris Therapeutics, Inc. Enters Agreement to be Acquired by Smith & Nephew plc
Sun, 11/25/2018 - 20:40 Osiris Therapeutics, Inc. Appoints Samson Tom, PhD, MBA to Serve as President and Chief Executive Officer
Mon, 10/29/2018 - 19:00 Osiris Therapeutics, Inc. to Present Advanced Clinical and Scientific Abstracts at Symposium on Advanced Wound Care (SAWC) Fall Meeting, November 2-4, 2018, in Las Vegas, Nevada
Mon, 10/01/2018 - 19:02 Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Demonstrating That Lyopreservation Method Developed for Living Tissues is an Alternative to Cryopreservation with the Convenience of Ambient Storage
Sun, 09/30/2018 - 19:59 Osiris Therapeutics, Inc. Announces GrafixPL PRIME Launches
Tue, 07/10/2018 - 19:51 Osiris Announces Enrollment of Patients in a Clinical Trial Evaluating GrafixPL PRIME in the Treatment of Chronic Venous Leg Ulcers
Wed, 04/25/2018 - 17:42 Osiris Announces New Peer-Reviewed Publication Summarizing Clinical Outcomes of Viable Cryopreserved Placental Membranes for Management of Chronic Diabetic Foot Ulcers in Real World Setting
Tue, 02/06/2018 - 15:21 Osiris Appoints Willi Miesch to its Board of Directors, Change in CEO
Thu, 11/02/2017 - 18:49 Osiris Therapeutics, Inc. Announces Resolution of SEC Investigation
Mon, 10/30/2017 - 16:01 Osiris Therapeutics, Inc. Provides Update on Audit of 2015 and 2016 Financial Statements
Mon, 10/23/2017 - 14:10 Osiris Announces a Peer-Reviewed Publication of a Scientific Study Reporting Antimicrobial Properties of Human Cryopreserved Viable Amniotic Membrane
Thu, 10/19/2017 - 12:30 Osiris Therapeutics to Present 10 Advanced Clinical and Scientific Abstracts, Including an Exclusive Oral Presentation on its New Ambient Viable Tissue Preservation Technology
Thu, 10/05/2017 - 13:01 Osiris Announces a Peer-Reviewed Publication Reporting the Use of Placental Membranes for Refractory Cutaneous Sinus Tracts of Surgical Origin
Mon, 06/26/2017 - 02:15 Osiris Appoints Linda Palczuk to serve as its President & CEO
Wed, 06/14/2017 - 13:03 Osiris Announces Electronically Available Case Study in a Peer-Reviewed Journal: Open Surgical Implantation of a Viable Cryopreserved Placental Membrane after Decompression and Neurolysis of Common Peroneal Nerve
Wed, 05/31/2017 - 15:15 Osiris Appoints David White to its Board of Directors
Tue, 04/04/2017 - 16:21 Osiris Therapeutics to Present 29 Advanced Clinical and Scientific Abstracts, Including a Late-Breaking Abstract on its New Ambient Viable Tissue Preservation Technology
more

InfoBox

HomePagewww.osiris.com
LinkedInwww.linkedin.com/company/osiris-therapeutics
Wikipediaen.wikipedia.org/wiki/Osiris_Therapeutics